BURDEN AND PREVENTION OF VIRAL HEPATITIS IN TURKEY

Viral Hepatitis Prevention Board
Istanbul, Turkey, November 12-13, 2009
The Viral Hepatitis Prevention Board

17 years of support to the control and prevention of viral hepatitis in Europe.
Content

- Viral Hepatitis Prevention Board (VHPB)
- VHPB activities
- Hepatitis B control in Europe
Viral Hepatitis Prevention Board

• The objective of VHPB is to contribute to the control and prevention of viral hepatitis
  - by drawing the attention to this important public health problem
  - by issuing prevention guidelines
  - and by encouraging actions to improve control and prevention.

• VHPB focus audiences are, in first instance, opinion leaders, policymakers, and health care professionals.
Viral Hepatitis Prevention Board

- VHPB was established in 1992. First actions related to hepatitis B as an occupational risk.
- World Health Assembly (1992): Integration of hepatitis B vaccine into national vaccination programmes.
- In 1993, VHPB started a second major initiative and focused on hepatitis B as a community health risk.
- The geographical focus was initially Western Europe, its actions are extended to include all 53 countries in the WHO/EURO
Support and Grants

- **VHPB secretariat**
  - based at the Center for the Evaluation of Vaccination (CEV) of the University of Antwerpen
  - CEV is designated as a WHOcc for control and prevention of viral hepatitis
  - infrastructure and administrative services of the University

- **supported by**
  - unrestricted grants from the vaccine industry GlaxoSmithKline Biologicals, Sanofi Pasteur MSD, Sanofi Pasteur and Merck
  - several universities and other institutions in Europe
  - GAVI fund and the CVP at PATH in the past for its activities in CEE and NIS.

- **strict operational and scientific independence is essential**
  - VHPB advisers and invited experts get only travel and subsistence reimbursed
  - according to the University Rules
  - no honorary or other forms of remuneration
Viral Hepatitis Prevention Board

- **Members**
  - WHO/EURO, WHO/HQ, ECDC, CDC, MOH, University experts

- network of experts
## VHPB ADVISERS

<table>
<thead>
<tr>
<th>WHO</th>
<th>University/ Hospital</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nedret Emiroglu</td>
<td>Selim Badur</td>
</tr>
<tr>
<td>Daniel Lavanchy</td>
<td>Paolo Bonanni</td>
</tr>
<tr>
<td>Steven Wiersma</td>
<td>Angela Dominguez</td>
</tr>
<tr>
<td><strong>duo seat: one of both will attend</strong></td>
<td>Wolfgang Jilg</td>
</tr>
<tr>
<td></td>
<td>Halène Norder*</td>
</tr>
<tr>
<td>WHO Regional office for Europe</td>
<td>Vana Papaevangelou</td>
</tr>
<tr>
<td></td>
<td>Françoise Roucrot-Thoraval</td>
</tr>
<tr>
<td></td>
<td>Rui Tato</td>
</tr>
<tr>
<td></td>
<td>Daniel Shouval</td>
</tr>
<tr>
<td></td>
<td>Alessandro Zanetti</td>
</tr>
<tr>
<td></td>
<td>Koer Van Herck</td>
</tr>
<tr>
<td>ECDC</td>
<td>Istanbul, Turkey</td>
</tr>
<tr>
<td>Marita Van de Laar</td>
<td>Florence, Italy</td>
</tr>
<tr>
<td></td>
<td>Barcelona, Spain</td>
</tr>
<tr>
<td></td>
<td>Regensburg, Germany</td>
</tr>
<tr>
<td></td>
<td>Solna, Sweden</td>
</tr>
<tr>
<td>CDC</td>
<td>Athens, Greece</td>
</tr>
<tr>
<td>John Ward</td>
<td>Paris, France</td>
</tr>
<tr>
<td></td>
<td>Lisbon, Portugal</td>
</tr>
<tr>
<td></td>
<td>Jersey, Israël</td>
</tr>
<tr>
<td></td>
<td>Milan, Italy</td>
</tr>
<tr>
<td>ELPA (European liver patients association)</td>
<td>Antwer, Belgium</td>
</tr>
<tr>
<td>Nicole Piorkowsky</td>
<td></td>
</tr>
<tr>
<td>Public Health Institute</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Hans Blystad</td>
<td></td>
</tr>
<tr>
<td>Claire Cameron/David Goldberg **</td>
<td></td>
</tr>
<tr>
<td>Johannes Hallauer</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Norway</td>
<td></td>
</tr>
<tr>
<td>Scotland</td>
<td></td>
</tr>
<tr>
<td>Germany</td>
<td></td>
</tr>
</tbody>
</table>

## Honorary members

<table>
<thead>
<tr>
<th>Pietro Crovari</th>
<th>Italy</th>
<th>Eric Mast</th>
<th>USA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alain Goudeau</td>
<td>France</td>
<td>Elisabeth McCloy</td>
<td>USA</td>
</tr>
<tr>
<td>Nicole Guérin</td>
<td>France</td>
<td>André Meneus</td>
<td>Belgium</td>
</tr>
<tr>
<td>Peter Grob</td>
<td>Swiss</td>
<td>Colette Roux</td>
<td>France</td>
</tr>
<tr>
<td>Mark Kane</td>
<td>USA</td>
<td>Craig Shapiro</td>
<td>USA</td>
</tr>
<tr>
<td>Harold Margolis</td>
<td>Korea</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Viral Hepatitis Prevention Board

- Meetings
  - 2 - 3 meetings/year (technical – country)
- *Viral Hepatitis* Newsletter
  - 2 issues/year
  - mailing to ± 4000 readers
- Web site
- Scientific publications
- Participation at Scientific Meetings
Editorial

This issue of Viral Hepatitis reviews the topics covered at the Viral Hepatitis Prevention Board (VHPB) autumn meeting held on November 17-18, 2005 in Edinburgh, United Kingdom (UK). The aim of the meeting was to review the current UK practice relating to the control of viral hepatitis. Health policy, healthcare delivery, decision-making, research, and funding in England, Wales, Scotland, and Northern Ireland were examined, in particular with regards to their implementation at national level. An update on the epidemiological situation of hepatitis A, hepatitis B, and hepatitis C in the UK was provided. Specific aspects of viral hepatitis were discussed, including virological and clinical aspects, control measures, public health perspectives, and economic evaluations. Preventive national and regional strategies for the control of viral hepatitis in the UK were then presented and assessed, including testing, vaccination, and treatment options. The meeting was concluded with lessons learnt from the UK experience and future challenges to be met.

Control of viral hepatitis in the UK - achievements and challenges

With regards to the decision-making process ensuring prevention of viral hepatitis, the need was recognised for a continuous evaluation of the current risk-group vaccination policy, to be compared with results obtained with alternative strategies, such as universal vaccination programmes, in other comparable countries of the European Union. The need to carefully monitor such alternative strategies implemented at the regional level in the UK was recognised. The need to target specific groups, such as immigrant populations, in preventive programmes and treatment was also identified.

In terms of chronic disease management, discussions focused on the need for national strategy and action plan in the case of hepatitis B while the establishment of Managed Clinical Networks (MCNs) should be ensured in the case of hepatitis C.

The control of viral hepatitis in the United Kingdom was also seen to be lacking a reliable surveillance system, based on standard laboratory reporting and case notifications. The need for enhanced epidemiological data was mentioned in or...
Viral Hepatitis Prevention Board

- Meetings
  - 2 - 3 meetings/year
- **Viral Hepatitis** Newsletter
  - 2 issues/year
  - mailing to ± 4000 readers
- Scientific publications
- Participation at Scientific Meetings
- Web site
Web site www.vhpb.org

- Overview of the VHPB
- Show all previous recommendations, guidelines and consensus statements
- All *Viral Hepatitis* issues as of 1996 can be downloaded
- Presentations of VHPB meetings are on-line since 2001 (>354 presentations of in total >448 documents)
WHO issued a review of the position paper on Hepatitis B vaccines.

The October 2 issue of the WHO periodical "Weekly Epidemiological Record" covered the latest WHO position paper on hepatitis B vaccines. To access it, go to:

All WHO position papers on vaccines are available in alphabetical order at http://www.who.int/immunization/documents/positionpapers.

Viral Hepatitis, Volume 17, Number 2, prepared from material presented at meeting 'Prevention and control of viral hepatitis in the Netherlands: Lessons learnt and the way forward' is online. 1,461Kb (.pdf)

This issue of Viral Hepatitis fully focuses on the Netherlands and reviews the organization of the healthcare system, the epidemiological situation, surveillance system, research activities, and current prevention and control measures of viral hepatitis. It also includes the meeting discussions that were particularly interesting as the Dutch Ministry of Health was re-evaluating the possible introduction of universal hepatitis B vaccination into the National Immunization programme at the time of this VHPB meeting.
Meetings and Recommendations

The VHPB has already covered a broad range of control and prevention strategies for all forms of hepatitis

- Surveillance
- Universal Immunisation programs
- Injection safety and safe blood supply
- HBV mutants and variants
- Prevention and control of viral hepatitis in migrants and refugees
- Behavioural issues in hepatitis B vaccination
- How to reach risk groups

- Combined vaccines
- Economic evaluations
- Hepatitis B vaccination safety issues
- Hepatitis B vaccine and long term efficacy
- Hepatitis infections in health care workers
- Perinatal transmission
- Adolescent programmes
- Patient and advocacy groups
REVIEW

Hepatitis A and B vaccination and public health

F. Blaine Hollinger,¹ B. Bell,² D. Levy-Bruhl,³ D. Shouval,⁴ S. Wiersma⁵ and P. Van Damme⁶

¹Baylor College of Medicine, Houston, TX, USA; ²Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, GA, USA; ³Institut de Veille Sanitaire, Saint-Maurice, France; ⁴Hadassah University Hospital, Jerusalem, Israel; ⁵World Health Organization, Geneva, Switzerland; and ⁶Center for the Evaluation of Vaccination, University of Antwerp, Antwerp, Belgium

Received July 2007; accepted for publication August 2007

SUMMARY. The introduction and implementation of hepatitis B vaccination programmes in areas of high endemicity has been very stressful. However, this initial accomplishment has led to the reassessment of priorities in some countries which could undermine these early successes. Work still remains to be done to support and implement interventions that will bring us closer to the WHO goal and to the control of hepatitis B in the community at large. Hepatitis A vaccine strategy for immunizing toddlers is shifting to those countries with intermediate endemicity where increasing morbidity in adults is being observed. Accumulating evidence indicates that such programmes can result in impressive reductions in the incidence of hepatitis A by herd immunity. Monitoring of these populations to determine durability of protection will be important to avoid shifting the infection to the older age population, when symptoms are more likely to occur. National policies need to consider hepatitis A vaccination in the context of other public health priorities.

Keywords: epidemiology, hepatitis A vaccine, hepatitis B vaccine, vaccine prevention.

INTRODUCTION

Hepatitis B immunization for infants and preschool children, even in low endemicity countries.
Has the time come to control hepatitis A globally? Matching prevention to the changing epidemiology


Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Antwerp, Belgium; Postdoctoral Fellow, Research Foundation – Flanders (FWO), Brussels, Belgium; Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, GA, USA; Department of Immunizations, Vaccines & Biologicals, World Health Organization, HQ, Geneva, Switzerland; Pan American Health Organization, Washington, DC, USA; and Liver Unit, Hadassah-Hebrew University Hospital, Jerusalem, Israel

SUMMARY. For the first time a global meeting on hepatitis A virus (HAV) infection as vaccine preventable disease was organized at the end of 2007. More than 200 experts from 46 countries gathered to investigate the changing global HAV epidemiology reflecting the increasing numbers of persons at risk for severe clinical disease and mortality from HAV infection. The benefits of childhood and adult hepatitis A (HepA) vaccination strategies and the data needed by individual countries and international health organizations to assess current HepA prevention strategies were discussed. New approaches in preventing HAV infection including universal HepA vaccination were considered. This introductory paper summarizes the major findings of the meeting and describes the changing epidemiology of HAV infections and the impact of HepA vaccination strategies in various countries. Implementation of HepA vaccination strategies should take into account the level of endemicity, the level of the socio-economic development and sanitation, and the risk of outbreaks. A stepwise strategy for introduction of HepA universal immunisation of children was recommended. This strategy should be based on accurate surveillance of cases and qualitative documentation of outbreaks and their control, secure political support on the basis of high-quality results, and comprehensive cost-effectiveness studies. The recognition of the need for increased global attention towards HepA prevention is an important outcome of this meeting.

Keywords: Global hepatitis A meeting, hepatitis A, hepatitis A vaccination, infectious disease control, public health, surveillance.
Benefits of Early Hepatitis B Immunization Programs for Newborns and Infants

Koen Van Herck, MD, PhD,* ‡ and Pierre Van Damme, MD, PhD*

Abstract: Despite the availability of safe and effective hepatitis B virus (HBV) vaccines for >20 years, strategies targeting risk groups failed to sufficiently control hepatitis B disease at the population level; this is mainly because of difficulties in risk identification and in program implementation. Hence, the global burden of disease of HBV still is substantial.

The World Health Organization recommends universal vaccination against hepatitis B to ultimately eliminate HBV; this recommendation had been progressively implemented to reach 168 countries with a universal program by the end of 2006. However, hepatitis B immunization is currently becoming endangered of losing its place on the agendas of governments, agencies, and international organizations, mainly because of the increasing success of these immunization programs and the interest in newer vaccine-preventable diseases and the related programs.

This publication aims to show that vaccination programs targeting newborns and infants are preferable to achieve this goal. The benefits of universal HBV vaccination for newborns and infants are: higher impact on chronic carrier rate and transmission; established potential of high vaccine coverage in this age group; opportunities to combine HBV vaccination with existing universal vaccination programs for newborns and infants; and impact on perinatal transmission, if vaccination is started shortly after birth. Moreover, the safety, immunogenicity, and long-term efficacy of newborn and infant HBV vaccination

Key Words: universal immunization, vaccination programs, hepatitis B vaccination, public health

The success of vaccination programs so far and the interest in other vaccine-preventable diseases have led to hepatitis B virus (HBV) vaccination becoming endangered of losing its place on the agenda of governments, agencies, and international organizations, a topic recently discussed at the Viral Hepatitis Prevention Board meeting in Istanbul, Turkey. Some agencies are downgrading HBV vaccination and have become reluctant to divert resources to HBV immunization programs, while clearly, the burden of HBV disease, compared with vaccine-preventable childhood diseases, is still substantial even in countries with low HBV endemicity. HBV infection continues to be a serious global health problem, with 2 billion people infected worldwide, and 350 million suffering from chronic HBV infection.

On the basis of HBV epidemiologic data, a mathematical model was developed to estimate the global hepatitis B disease burden and vaccination impact. During the lifetime of the year 2000 worldwide birth cohort, the model estimates that without vaccination there would be 64,766,000 HBV infections: 9,733,000 chronic infections; and 1,405,000 HBV-related
Country meetings

- Italy 2002
- Germany and the Nordic Countries 2003
- France 2004
- UK 2005
- Spain 2006
- Greece 2007
- The Netherlands 2008
- Turkey 2009
BURDEN AND PREVENTION OF VIRAL HEPATITIS IN TURKEY

Viral Hepatitis Prevention Board
Istanbul, Turkey, November 12-13, 2009
Objectives of the meeting

- Provide an overview of surveillance systems for infectious diseases;
- Review the epidemiological situation on viral hepatitis;
- Give an overview of the current prevention and control measures on viral hepatitis;
- Discuss the progress achieved in hepatitis prevention 10 years after the introduction of Universal Hepatitis B vaccination;
- Review the possible implementation of new prevention strategies, control measures and monitoring systems.
- Discuss the successes, problems and barriers to overcome, and the way forward